Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-24T05:49:23.023Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment of bleeding following cardiopulmonary bypass in neonates and infants

Published online by Cambridge University Press:  19 August 2008

Wulf Dietrich ,
Hansjörg J. Mössinger  and
Josef A. Richter
Wulf Dietrich*
Affiliation:
From the Deutsches Herzzentrum München, München
Hansjörg J. Mössinger
Affiliation:
From the Deutsches Herzzentrum München, München
Josef A. Richter
Affiliation:
From the Deutsches Herzzentrum München, München
*
Dr. WulfDietrich, German Heart Center Munich, Department of Anesthesia, Lothstraße 11, 8000 München 2, Germany. Tel. (089) 1209-301.
Get access Rights & Permissions [Opens in a new window]

Extract

Bleeding after cardiopulmonary bypass remains a significant problem for the cardiac surgeon. In addition to surgically-induced bleeding, the major cause of loss of blood is an acquired coagulopathy. Impaired function, produced either by the mechanical effect of cardiopulmonary bypass or by the influence of hemostatic activation of platelets during bypass, is the main cause of postoperative bleeding. The tendency towards bleeding in infants and neonates is additionally influenced by the type of operation, those with cyanotic heart disease demonstrating an increased tendency to bleeding. Most of the procedures are more complex than in adults, and many reoperations are necessary, particularly if primary correction is not possible. Furthermore, procedures for perfusion and cooling are mostly different from those used in adults. The operations are regularly performed using deep hypothermia or circulatory arrest, which may further impair the function of platelets. Yet the effect of low temperatures on hemostasis, with or without circulatory arrest, still remains unclear, since the immature system for coagulation in neonates may contribute to impaired hemostasis.

Keywords

Hemostasisplateletsactivation of clottingdeep hypothermia
Type
World Forum for Pediatric Cardiology Symposium on Cardiopulmonary Bypass (Part 1)
Information
Cardiology in the Young , Volume 3 , Issue 3 , July 1993 , pp. 257 - 262
Copyright
Copyright © Cambridge University Press 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Woodman, RC, Harker, LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990; 76: 1680–1697.CrossRefGoogle ScholarPubMed
2.Valeri, C, Cassidy, G, Khuri, S, Feingold, H, Ragno, G, Altschulte, M. Hypothermia-induced reversible platelet dysfunction. Ann Surg 1987; 205: 175–181.CrossRefGoogle ScholarPubMed
3.McClure, P, Izsak, J. The use of epsilon-aminocaproic acid to reduce bleeding during cardiac bypass in children with con genital heart disease. Anesthesiology 1974; 40: 604–608.CrossRefGoogle Scholar
4.Andrew, M, Bhogal, M, Karpatkin, M. Factors XI and XII and prekallekrein in sick and healthy premature infants. N Engl J Med 1981; 305: 1130–1133.CrossRefGoogle ScholarPubMed
5.Ming, Y, Simon, N, Maertens, P, Brigham, S, Liu, P. Maternal-fetal transport of vitamin KI and its effect on coagulation in premature infants. J Pediatr 1989; 115: 1009–1013.Google Scholar
6.Kirklin, JK, Westaby, S, Blackstone, EH, Kirklin, JW, Chenoweth, DE, Pacifico, AD. Complement and the demaging effects of cardiopulmonary bypass. J Thorac Cardiaovasc Surg 1983; 86: 845–857.CrossRefGoogle Scholar
7.Greeley, W, Bushman, G, Kong, D, Oldham, HN, Peterson, M. Effects of cardiopulmonary bypass on eicanoid metabolism during pediatric cardioavascular surgery. J Thorac Cardiaovasc Surg 1988; 95: 842–849.CrossRefGoogle Scholar
8.Fleming, W, Saraflan, L, Leschen, M, Newland, M, Kennedy, E, Kugler, J, Chapin, J, Hurlber, B, Bolam, D, Nelson, R. Serum concentrations of prostacyclin and thromboxane in children before, during, and after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1986; 92: 73–78.CrossRefGoogle ScholarPubMed
9.Salzman, EW, Weinstein, MJ, Weintraub, RM, Ware, JA, Thurer, RL, Robertson, L, Donovan, A, Gaffney, T, Bertele, V, Troll, J, Smith, M, Chute, LE. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. N Engl J Med 1986; 314: 1402–1406.CrossRefGoogle ScholarPubMed
10.Kappa, JR, Horn, D, Nclntosh, CL, Fisher, CA, Ellison, N, Addonizio, VP. Iloprost (ZK 36374), a new prostacyclin analogue, permits open cardiac operation in patients with heparin-induced thrombocytopenia. Surg Forum 1985; 36: 285–286.Google Scholar
11.Horrow, JC, Hiavacek, J, Strong, MD, Collier, W, Brodsky, I, Goldmann, SM, Goel, IP. Prophylactic tranexamic acid de creases bleeding after cardiac operations. J Thorac Cardiovasc Surg 1990; 99: 70–74.CrossRefGoogle Scholar
12.Fritz, H, Wunderer, G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneim Forsch/Drug Res 1983; 33: 479–494.Google Scholar
13.Royston, D, Taylor, KM, Bidstrup, BP, Sapsford, RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987; ii: 1289–1291.CrossRefGoogle Scholar
14.Bidstrup, BP, Royston, D, Sapsfort, RN, Taylor, KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989; 97: 364–372.CrossRefGoogle ScholarPubMed
15.van Oeveren, W, Jansen, NJG, Bidstrup, BP, Royston, D, Westaby, S, Neuhof, H, Wildevuur, CRH. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 1987; 44: 640–645.CrossRefGoogle ScholarPubMed
16.Dietrich, W, Spannagl, M, Jochum, M, Wendt, P, Schramm, W, Barankay, A, Sebening, F, Richter, JA. Influence of high-dose aprotinin treatment on blood loss and coagulation pattern in patients undergoing myocardial revascularization. Anesthesiology 1990; 73: 1119–1126.CrossRefGoogle ScholarPubMed
17.Blauhut, B, Gross, C, Necek, S, Doran, JE, Spath, P, Lundsgaardhansen, P. Effects of high-dose aprotinin on blood ioss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 101: 958–967.CrossRefGoogle Scholar
18.Lu, H, Soria, C, Commin, PL, Soria, J, Piwnica, A, Schumann, F, Regnier, O, Legrand, Y, Caen, JP. Hemostasis in patients undergoing extracorporeal circulation: the effect of aprotinin (Trasylol). Thromb Haemost 1991; 66: 633–637.Google ScholarPubMed
19.Dietrich, W, Barankay, A, Hahnel, C, Richter, JA. High-dose aprotinin in cardiac surgery: three years' experience in 1,784 patients. J Cardiothorac Vasc Anesth 1992; 6: 324–327.CrossRefGoogle ScholarPubMed
20.Cosgrove, D, Heric, B, Lytle, B, Taylor, P, Novoa, R, Golding, L, Stewart, R, McCarthy, P, Loop, F. Aprotinin therapy for reoperative myocardial revascularization: a placebo controlled study. Ann Thorac Surg 1992; 54: 1031–1038.CrossRefGoogle ScholarPubMed
21.Seear, MD, Wadsworth, LD, Rogers, PC, Sheps, S, Ashmore, PG. The effect ofdesmopressin acetate on postoperative blood loss after cardiac operations in children. J Thorac Cardiovasc Surg 1989; 98: 217–219.CrossRefGoogle ScholarPubMed
22.Popov-Cenic, S, Urban, AE, Noë, G. Studies on the cause of bleeding during and after surgery with a heart-lung machine in children with cyanotic and acyanotic congenital cardiac defects and their prophylactic treatment. In: McConn, R (ed). The Role of Chemical Mediators in the Pathophysiology of Acute Ilness and Injury. Raven Press, New York, 1982, pp 229–242.Google Scholar
23.Dietrich, W, Mössinger, H, Spannagl, M, Jochum, M, Wendt, P, Barankay, A, Meisner, H, Richter, J. Hemostatic activation during cardiopulmonary bypass in pediatric cardiac surgicalpatients with different aprotinin doses. J Thorac Cardiovasc Surg; 1993. [In press]CrossRefGoogle Scholar
24.Furie, B, Furie, BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992; 326: 800–806.Google ScholarPubMed
25.Dietrich, W, Richter, JA, Schramm, W, Spannagi, M. What is the mechanism of action of aprotinin-reply. Anesthesiology 1991; 75: 378–379.CrossRefGoogle Scholar
26.Verstraete, M. Clinical application of inhibitors of fibrinolysis. Drugs 1985; 29: 236–261.CrossRefGoogle ScholarPubMed
27.Winters, K, Santoro, S, Miletich, J, Eisenberg, P. Relative importance of thrombin compared with plasmin-mediated platelet activation in response to plasminogen activation with streptokinase. Circulation 1991; 84: 1552–1560.CrossRefGoogle ScholarPubMed
28.Lavee, J, Savion, N, Smolinsky, A, Goor, DA, Mohr, R. Platelet protection by aprotinin in cardiopulmonary bypass: electron microscopic study. Ann Thorac Surg 1992; 53: 477–481.CrossRefGoogle ScholarPubMed
29.Mössinger, H, Dietrich, W, Spannagel, M, Heuze, R, Barankay, A, Richter, JA. High dose aprotinin reduces not only fibrin olytic, but also clotting activation in pediatric cardiac surgery. SCA Annual Meeting, San Diego 1993. [In press]Google Scholar
30.Harker, LA. Bleeding after cardiopulmonary bypass. N EngI J Med 1986; 314: 446–448.CrossRefGoogle ScholarPubMed
31.Elliott, M, Allen, A. Aprotinin in pediatric cardiac surgery. Perfusion 1990; 5: 73–76.CrossRefGoogle Scholar
32.Muller, H, Alken, A, Ziemer, G, Hirt, S, Schaps, D. Aprotinin in pediatric cardiopulmonary bypass surgery. J Cardiothorac Vasc Anesth 1992; 6: 100.CrossRefGoogle Scholar
33.Boldt, J, Knothe, C, Zickmann, B, Dapper, F, Hempelmann, G. Comparison oftwo aprotinin dose regimes in pediatric cardiac surgery: influence on platelet function and blood loss. J Thorac Cardiovasc Surg 1993. [In press]Google Scholar
34.Urban, AE, Brecher, AM, Popov-Cenic, S. Blutungen nach intrakardialen operativen Eingriffen im Säuglingsalter: Klinische Relevanz und perioperative Therapie. In: R, Dudziak, PG, Kirchhoff, HD, Reuter, F, Schumann (eds). Proteolyse und Proteinaseninhibition in Herz-und Gefäßchirurgie. Schattauer, Stuttgart, 1985, pp 273–278.Google Scholar
35.Böhrer, H, Bach, A, Fleischer, F, Lang, J. Adversehaemodynamic effects of high-dose aprotinin in a pediatric cardiac surgical patient. Anaesthesia 1990; 45: 853–854.CrossRefGoogle Scholar
36.Andrew, M, Schmidt, B. Use of heparin in newborn infants. Sem Thromb Hemostas 1988; 14: 28–32.CrossRefGoogle ScholarPubMed
37.Dietrich, W, Spannagl, M, Schramm, W, Vogt, W, Barankay, A, Richter, J. The influence of preoperative anricoagulation on heparin response during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 102: 505–514.CrossRefGoogle Scholar
38.Weitz, J, Hudoba, M, Massel, D, Maraganore, J, Hirsch, J. Clot-bound thrombin is protected from inhibition by heparin antithrombin III but is susceptible to inactivation by an tithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385–391.CrossRefGoogle ScholarPubMed
39.Wang, J, Lin, C, Hung, W, Karp, R. Monitoring of heparin induced anticoagulation with koalin-activated clotting time in cardiac surgical patients treated with aprotinin. Anesthesiology 1992; 77: 1080–1084.CrossRefGoogle ScholarPubMed
40.Dietrich, W, Spannagl, M, Mössinger, HJ, Richter, JA. Fibrin formation during cardiopulmonary bypass with and without circulatory arrest in operations of congenital heart diseases. Anesthesiology 1991; 75: A76.CrossRefGoogle Scholar